Literature DB >> 16764342

Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.

E Fainardi1, M Castellazzi, T Bellini, M C Manfrinato, E Baldi, I Casetta, E Paolino, E Granieri, F Dallocchio.   

Abstract

In this study, we employed a sensitive activity assay system to measure cerebrospinal fluid (CSF) and serum levels of active matrix metalloproteinase-9 (MMP-9) in 37 relapsing-remitting (RR), 15 secondary progressive (SP) and nine primary progressive (PP) multiple sclerosis (MS) patients, grouped according to clinical and magnetic resonance imaging (MRI) evidence of disease activity. We also studied, as neurological controls, 48 patients with other inflammatory neurological disorders (OIND) and 48 with non-inflammatory neurological disorders (NIND). To assess active MMP-9/TIMP-1 circuit, CSF and serum levels of MMP-9 tissue inhibitor TIMP-1 were quantified by ELISA in the same patient population. CSF mean levels of active MMP-9, CSF active MMP-9/TIMP-1 ratios and intrathecal active MMP-9 synthesis, as indicated by specific index, were more elevated in MS than in NIND (P < 0.05, < 0.02 and < 0.02, respectively), serum active MMP-9/TIMP-1 ratio was higher in MS (P < 0.01) and OIND (P < 0.02) than in NIND, and serum TIMP-1 concentrations were lower in MS than in NIND (P<0.05). More importantly, serum active MMP-9 mean levels, serum active MMP-9/TIMP-1 ratio and intrathecal production of active MMP-9 were increased in MS patients with clinical (P < 0.001, < 0.001 and < 0.05, respectively) and MRI (P < 0.001, < 0.001 and < 0.02, respectively) disease activity, whereas CSF mean concentrations of active MMP-9 and CSF active MMP-9/TIMP-1 ratio were enhanced only in MS patients with MRI evidence of disease activity (P < 0.02 and < 0.01, respectively). Altogether, these findings suggest that a shift in MMP-9/TIMP-1 balance towards proteolytic activity of MMP-9 could be relevant in MS immune dysregulation. In addition, our results indicate that CSF and serum levels of active MMP-9 may represent a potential surrogate biomarker for monitoring MS disease activity. In particular, serum active MMP-9/TIMP-1 ratio seems to be a very appropriate indicator of ongoing MS inflammation, since it is easily measurable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16764342     DOI: 10.1191/135248506ms1274oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  38 in total

1.  Cleavage of myelin associated glycoprotein by matrix metalloproteinases.

Authors:  Elizabeth Milward; Kee Jun Kim; Arek Szklarczyk; Thien Nguyen; Giorgia Melli; Mamatha Nayak; Deepa Deshpande; Chantel Fitzsimmons; Ahmet Hoke; Douglas Kerr; John W Griffin; Peter A Calabresi; Katherine Conant
Journal:  J Neuroimmunol       Date:  2007-12-11       Impact factor: 3.478

2.  Assessment and Treatment Strategies for a Multiple Sclerosis Relapse.

Authors:  Cynthia Wang; America Ruiz; Yang Mao-Draayer
Journal:  J Immunol Clin Res       Date:  2016-12-07

3.  Multimodal Molecular Imaging Demonstrates Myeloperoxidase Regulation of Matrix Metalloproteinase Activity in Neuroinflammation.

Authors:  Yinian Zhang; Huateng Dong; Daniel P Seeburg; Gregory R Wojtkiewicz; Peter Waterman; Benjamin Pulli; Reza Forghani; Muhammad Ali; Yoshiko Iwamoto; Filip K Swirski; John W Chen
Journal:  Mol Neurobiol       Date:  2018-05-28       Impact factor: 5.590

4.  Detection of Matrix Metalloproteinases by Zymography.

Authors:  Rajeev B Tajhya; Rutvik S Patel; Christine Beeton
Journal:  Methods Mol Biol       Date:  2017

Review 5.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

6.  Cerebrospinal fluid in multiple sclerosis.

Authors:  Kottil W Rammohan
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

Review 7.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

Review 8.  Th17 cells in human disease.

Authors:  Laura A Tesmer; Steven K Lundy; Sujata Sarkar; David A Fox
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

Review 9.  The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis.

Authors:  Abbas Mirshafiey; Babak Asghari; Ghasem Ghalamfarsa; Farhad Jadidi-Niaragh; Gholamreza Azizi
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

10.  Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta.

Authors:  Zohara Sternberg; Kailash Chadha; Alicia Lieberman; Allison Drake; David Hojnacki; Bianca Weinstock-Guttman; Frederick Munschauer
Journal:  J Neuroinflammation       Date:  2009-10-13       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.